

**Louisiana Department of Health  
Medicaid Pharmaceutical and Therapeutics Committee  
628 North Fourth Street  
Baton Rouge, LA  
Bienville Building  
Room #118  
November 6, 2019  
9:00 AM**

- I. Call to Order.....Marty McKay
- II. Parliamentary Business .....Marty McKay
  - A. Introduction of Members/Roll Call
  - B. Approval of April 26, 2019 Meeting Minutes
  - C. P & T Bylaws – Proposed Amendments.....Kimberly Sullivan/Haley Williams
- III. Ethics Reminders.....Haley Williams
- IV. Reports.....Melwyn Wendt
  - A. Prior Authorization Monthly Report
  - B. PDL Reflecting April 26, 2019 P&T Committee Recommendations (Single PDL)
- V. New Business.....Hind Douiki
  - A. Explanation of TOP\$, Monographs and Cost Sheets
  - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
    - 1. Alzheimer’s Agents
    - 2. Antidepressants, Other
    - 3. Antidepressants, SSRIs
    - 4. Antihistamines, Minimally Sedating
    - 5. Antihypertensives, Sympatholytics
    - 6. Antihyperuricemics
    - 7. Antiparkinson’s Agents
    - 8. Antipsoriatics, Oral
    - 9. Antipsoriatics, Topical
    - 10. Antipsychotics
    - 11. Anxiolytics
    - 12. Bile Salts
    - 13. Bronchodilators, Beta Agonist
    - 14. Colony Stimulating Factors
    - 15. COPD Agents
    - 16. Cytokine and CAM Antagonists
    - 17. Emollients
    - 18. Epinephrine, Self-Injected
    - 19. Erythropoiesis Stimulating Proteins
    - 20. Glucocorticoids, Inhaled

21. Glucocorticoids, Oral
22. Hemophilia Treatment
23. Histamine II Receptor Blocker
24. Immunomodulators, Atopic Dermatitis
25. Immunomodulators, Topical
26. Intranasal Rhinitis Agents
27. Leukotriene Modifiers
28. Methotrexate – New
29. Movement Disorders - New
30. Neuropathic Pain
31. NSAIDs
32. Oncology Oral – Breast
33. Oncology Oral – Hematologic
34. Oncology Oral - Lung
35. Oncology Oral – Other
36. Oncology Oral – Prostate
37. Oncology Oral – Renal Cell
38. Oncology Oral - Skin
39. Ophthalmic, Antibiotic-Steroid Combinations
40. Ophthalmic Antibiotics
41. Ophthalmics for Allergic Conjunctivitis
42. Ophthalmics, Anti-Inflammatories
43. Ophthalmics, Anti-Inflammatories/ Immunomodulator
44. Ophthalmics, Glaucoma Agents
45. Otic Anti-Infectives & Anesthetics
46. Otic Antibiotics
47. Progestational Agents
48. Sedative Hypnotics
49. Smoking Cessation
50. Steroids, Topical High
51. Steroids, Topical Low
52. Steroids, Topical Medium
53. Steroids, Topical Very High
54. Stimulants and Related Agents

VI. New Single Drug Reviews.....Hind Douiki

55. Antimigraine Agents, Other – Emgality® Syringe 100 mg
56. Bone Resorption Suppression and Related Agents – Evenity®
57. Immunosuppressives, Oral – Prograf® Granules Pack
58. Lipotropics, Statins – Ezallor® Sprinkle
59. Multiple Sclerosis Agents – Mayzent®
60. Multiple Sclerosis Agents – Mavenclad®
61. Skeletal Muscle Relaxants – Norgestic Forte®

VII. Other Business

- VIII. Next Steps
  - A. Proposed Therapeutic Classes to be Reviewed at Next Meeting
- IX. Next Meeting Date – Friday, April 24, 2020
- X. Public Testimony